Nanobiotix (NBTX) Financials: Revenue & Earnings
NBTX$33.34-0.64 -1.88%
$1.55B
Market Cap
-27.47
P/E
75.07
Forward P/E
33
Score
Nanobiotix (NBTX) Financials: Revenue & Earnings
NBTX price $33.34 -0.64 -1.88%
- Ticker
- NBTX
- Price
- $33.34
- Change
- -0.64 -1.88%
- Market cap ?
- $1.55B
- P/E ?
- -27.47
- Forward P/E ?
- 75.07
- Dividend yield ?
- 0.00%
- Beta ?
- 0.57
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 33
- Value
- 56
- Quality
- 22
- Growth
- 20
Stocklytics score rationale: value 56, quality 22, growth 20.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 5421613 | 3722000 | 3479000 | 2541000 | 2325000 | 2647000 | 4776000 | 36208000 | -7190000 | 29643000 |
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and…
Earnings and financials
Nanobiotix S.A. (NBTX) trades at $33.34, with a market cap of $1.55B and a trailing P/E of -27.47. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 5421613 | 3722000 | 3479000 | 2541000 | 2325000 | 2647000 | 4776000 | 36208000 | -7190000 | 29643000 |
Insights · Dividends · Forecast · Financials · Learn